Ambeed.cn

首页 / / / / GSK2656157

GSK2656157 {[allProObj[0].p_purity_real_show]}

货号:A184177

GSK2656157对蛋白激酶R(PKR)样内质网激酶(PERK)显示出选择性和ATP竞争性抑制作用,IC50为0.9 nM。

GSK2656157 化学结构 CAS号:1337532-29-2
GSK2656157 化学结构
CAS号:1337532-29-2
GSK2656157 3D分子结构
CAS号:1337532-29-2
GSK2656157 化学结构 CAS号:1337532-29-2
GSK2656157 3D分子结构 CAS号:1337532-29-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

GSK2656157 纯度/质量文件 产品仅供科研

货号:A184177 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 PERK 其他靶点 纯度
ISRIB ++

PERK, IC50: 5 nM

98%
GSK2656157 +++

PERK, IC50: 0.9 nM

99%+
GSK2606414 ++++

EIF2AK3 (PERK), IC50: 0.4 nM

99%+
Salubrinal 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

GSK2656157 生物活性

靶点
  • PERK

    PERK, IC50:0.9 nM

描述 UPR (unfolded protein response), dysregulation of which has been implicated in many important pathologies, is an essential pathway to cope with ER stress. PERK is one of three primary effectors of the UPR. It can be activated by the released ER chaperones caused by increase of unfolded proteins in the ER and thus phosphorylates eIF2α. GSK2656157 is a potent and selective PERK inhibitor with IC50 value of 0.9nM on PERK enzyme activity, highly selective for PERK with IC50 values >100nM against a panel of 300 kinases. Pretreatment with GSK2656157 at concentration ranging in 10-30nM resulted in block of UPR activated by thapsigargin or tunicamycin, including autophosphorylation of PERK and its downstream substrates as p-eIF2α, ATF4 and CHOP in BxPC3 cells. The transcription of a series of tunicamycin-induced UPR gene was attenuated by 1μM GSK2656157 in the same cell line, including CHOP, HERP, ERO1LB, DNAJB9, SEL1L, etc.. Complete inhibition of pPERK-Thr980 can be observed through 8h after a single oral dose of 50mg/kg GSK2656157 In vivo, which showed the pharmacokinetic properties of this compound, without effect on p-eIF2α-S51 level. Oral dose of 50mg/kg or 150mg/kg GSK2656157 twice daily resulted in varying degrees of tumor growth inhibition in mice bearing various human tumor xenografts, including by 61% tumor growth inhibition in BxPC3 pancreas xenografts, by 47% and 65% in NCI-H929 multiple myeloma xenografts, by 31% and 54% in HPAC pancreas xenografts and by 107% and 114% in Capan2 pancreas xenografts. After treatment with 50mg/kg or 150mg/kg GSK2656157 for 3 weeks, a decrease in blood vessel density in tumors can be observed in BxPC3 tumor-bearing mice[1].
作用机制 GSK2656157 is an ATP-competitive PERK inhibitor.[1]

GSK2656157 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human A549 cells Function assay 1 h Inhibition of thapsigargin-induced autophosphorylation of PERK in human A549 cells preincubated for 1 hr followed by thapsigargin-induction measured after 1 hr by Western blotting analysis, IC50=0.03 μM 24900593

GSK2656157 动物研究

Dose Mice[1] (p.o.): 1.5 mg/kg - 150 mg/kg
Administration p.o.
Pharmacokinetics
Animal Mice[2] Rats[2] Dogs[2]
Dose 2 mg/kg 2.2 mg/kg 2.9 mg/kg
Administration i.v. i.v. i.v.
AUC0→inf 3270 ng·h/ml 3128.5 ng·h/ml
CLb 10.5 ml/min/kg 9.5 ml/min/kg 15.5 ml/min/kg
AUC0-inf 3921 ng·h/ml
Vdss 0.72 L/kg 0.6 L/kg 2.8 L/kg

GSK2656157 参考文献

[1]Axten JM, Romeril SP, et al. Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development. ACS Med Chem Lett. 2013 Aug 12;4(10):964-8.

GSK2656157 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.01mL

2.40mL

1.20mL

24.01mL

4.80mL

2.40mL

GSK2656157 技术信息

CAS号1337532-29-2
分子式C23H21FN6O
分子量 416.451
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 7 mg/mL(16.81 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

1M HCl: 100 mg/mL(240.12 mM),配合低频超声,并调节pH至1

动物实验配方

1% CMC Na+water 30 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。